Rosenberg SA et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319(25):1676–1680. https://doi.org/10.1056/NEJM198812223192527

Article  CAS  PubMed  Google Scholar 

Ben-Avi R et al (2018) Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother 67(8):1221–1230. https://doi.org/10.1007/s00262-018-2174-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dudley ME et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850–854. https://doi.org/10.1126/science.1076514

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manfredi F et al (2020) TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Front Immunol 11. Accessed: Dec. 28, 2022. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01689

Alnefaie A et al (2022) Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol 10. Accessed: Jan. 09, 2023. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440

Sheridan C (2017) First approval in sight for Novartis’ CAR-T therapy after panel vote. Nature Biotechnol 35(8). https://doi.org/10.1038/nbt0817-691

Ahmed N et al (2015) Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. JCO 33(15):1688–1696. https://doi.org/10.1200/JCO.2014.58.0225

Article  CAS  Google Scholar 

Heczey A et al (2017) CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther 25(9):2214–2224. https://doi.org/10.1016/j.ymthe.2017.05.012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lamers CHJ, Klaver Y, Gratama JW, Sleijfer S, Debets R (2016) Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overview. Biochem Soc Trans 44(3):951–959. https://doi.org/10.1042/BST20160037

Article  CAS  PubMed  Google Scholar 

Louis CU et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma. Blood 118(23):6050–6056. https://doi.org/10.1182/blood-2011-05-354449

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parkhurst MR et al (2011) T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Mol Ther 19(3):620–626. https://doi.org/10.1038/mt.2010.272

Article  CAS  PubMed  Google Scholar 

Shi D et al (2020) Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clin Cancer Res 26(15):3979–3989. https://doi.org/10.1158/1078-0432.CCR-19-3259

Article  CAS  PubMed  Google Scholar 

Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clinicians 71(3): 209–249. https://doi.org/10.3322/caac.21660

Larson SM et al (2023) CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov 13(3):580–597. https://doi.org/10.1158/2159-8290.CD-22-0964

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu J et al (2023) CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer J 13(1). https://doi.org/10.1038/s41408-023-00813-x

Labani-Motlagh A, Ashja-Mahdavi M, Loskog A (2020) The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Front Immunol 11. Accessed: Dec. 29, 2022. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2020.00940

Konjević GM, Vuletić AM, Mirjačić Martinović KM, Larsen AK, Jurišić VB (2019) The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine 117:30–40. https://doi.org/10.1016/j.cyto.2019.02.001

Article  CAS  PubMed  Google Scholar 

Huang AC, Zappasodi R (2022) A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol 23(5). https://doi.org/10.1038/s41590-022-01141-1

Ager A, Watson HA, Wehenkel SC, Mohammed RN (2016) Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem Soc Trans 44(2):377–385. https://doi.org/10.1042/BST20150254

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes CE, Nibbs RJB (2018) A guide to chemokines and their receptors. FEBS J 285(16):2944–2971. https://doi.org/10.1111/febs.14466

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng W et al (2022) Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. Cancer Cell Int 22(1):186. https://doi.org/10.1186/s12935-022-02604-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

House IG et al (2020) Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res 26(2):487–504. https://doi.org/10.1158/1078-0432.CCR-19-1868

Article  CAS  PubMed  Google Scholar 

Zsiros E et al (2015) The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clin Cancer Res 21(12):2840–2850. https://doi.org/10.1158/1078-0432.CCR-14-2777

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karaki S et al (2021) CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors. J Immunother Cancer 9(3):e001948. https://doi.org/10.1136/jitc-2020-001948

Article  PubMed  PubMed Central  Google Scholar 

Rapp M et al (2016) C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology 5(3):e1105428. https://doi.org/10.1080/2162402X.2015.1105428

Article  CAS  PubMed  Google Scholar 

Garetto S et al (2016) Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model. Oncotarget 7(28):43010–43026. https://doi.org/10.18632/oncotarget.9280

Article  PubMed  PubMed Central  Google Scholar 

Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P (2016) Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer 4:21. https://doi.org/10.1186/s40425-016-0125-1

Article  PubMed  PubMed Central  Google Scholar 

Craddock JA et al (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33(8):780–788. https://doi.org/10.1097/CJI.0b013e3181ee6675

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moon EK et al (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17(14):4719–4730. https://doi.org/10.1158/1078-0432.CCR-11-0351

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y et al (2021) Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model. Front Immunol 12:628906. https://doi.org/10.3389/fimmu.2021.628906

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lesch S et al (2021) T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat Biomed Eng 5(11):1246–1260. https://doi.org/10.1038/s41551-021-00737-6

Article  CAS  PubMed